Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
End stage kidney disease
How can narrative medicine be used to potentially improve outcomes for patients on dialysis?
Related Questions
Do you use a profile with high ultrafiltration rates interrupted by UF pauses to manage ESKD patients prone to intradialytic hypotension?
Do you prefer maximizing fluid removal during dialysis or starting new antihypertensive medications for patients with ESKD on intermittent hemodialysis who are chronically hypertensive?
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
Do you recommend patients with ESKD time their daily B complex multivitamin to after hemodialysis on hemodialysis days?
Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
What is your approach to dosing sodium thiosulfate for a patient with ESKD who is receiving CRRT?
How would you approach managing a patient with ESKD on peritoneal dialysis who has a milky appearance of peritoneal effluent but low peritoneal fluid triglyceride levels?
Which ESKD patients would you consider transitioning from hemodialysis to hemodiafiltration, given the FDA approval of a hemodiafiltration system in the US?
Do you recommend prophylactically adding heparin to the dialysate in patients hospitalized for peritoneal dialysis associated peritonitis given higher incidence of fibrin-associated catheter issues?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
